STRS Ohio’s Artiva Biotherapeutics ARTV Stock Holding History

STRS Ohio’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,600	Closed	-$40.2K	–	2083
2024 Q3	$40.2K	Buy	+2,600	New	+$30.1K	﹤0.01%	1834

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

STRS Ohio's ARTV Position: Q4 2024 in Review

STRS Ohio sold out of Artiva Biotherapeutics (ARTV) in Q4 2024, closing a stake of 2,600 shares — an estimated $40.2K sold.

STRS Ohio first reported a position in ARTV in Q3 2024 and held it in 1 quarter. The position peaked at $40.2K in Q3 2024. 57 funds tracked by Wall St. Rank hold ARTV as of Q4 2024.

STRS Ohio reported no remaining Artiva Biotherapeutics position as of Q4 2024 after selling out during the quarter.
STRS Ohio sold 2,600 Artiva Biotherapeutics shares in Q4 2024, an estimated $40.2K.
STRS Ohio first reported a position in Artiva Biotherapeutics in Q3 2024 and held it in 1 quarter.
STRS Ohio's Artiva Biotherapeutics position peaked at $40.2K in Q3 2024.
57 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q4 2024.

Based on STRS Ohio's 13F filing for Q4 2024, filed 28 May 2025.